InfuSystem Holdings, Inc. filings document financial reporting, governance and material-event disclosures for a health care service provider focused on outpatient durable medical equipment services. Recent 8-K filings furnish earnings releases, conference-call announcements, investor presentations and Regulation FD disclosures tied to Patient Services and Device Solutions.
The company’s proxy materials cover board matters, shareholder voting, executive compensation and equity award disclosures. Other filings document accounting oversight, including changes in the independent registered public accounting firm, audits of consolidated financial statements and internal control over financial reporting.
InfuSystem Holdings, Inc. (INFU) reported third-quarter 2026 revenue of $37.6 million, up 3.0% year over year, and net income of $3.2 million, versus $2.3 million a year earlier. Adjusted EBITDA, a non-GAAP measure, was $9.4 million, up 12.5%; its margin was 24.9%, versus 22.8%. Patient Services revenue rose 15.4% to $25.8 million, while Device Solutions revenue fell 16.6% to $11.8 million.
After adjusting for the GE Healthcare contract restructuring, third-quarter pro forma revenue growth was 10.2%; the restructuring reduced quarterly revenue by $2.4 million. Nine-month operating cash flow was $18.1 million, up 5%. The company cited approximately $5.0 million of temporary working-capital pressure related to ERP billing disruptions; approximately $1.3 million had converted to cash based on October collections. Liquidity was $64.1 million as of September 30, 2026. InfuSystem reaffirmed 2026 pro forma revenue growth guidance of 6% to 8% and an Adjusted EBITDA margin in the low-to-mid 20% range.
InfuSystem Holdings, Inc. (INFU) postponed its third-quarter 2026 financial-results release, previously scheduled for November 3, 2026, to allow additional time to complete quarter-end reporting. The company expects to announce a revised date for the results release and related conference call as soon as practicable.
InfuSystem, its Audit Committee and its independent registered public accounting firm are evaluating whether $4.2 million of implementation costs for the ERP system should be capitalized and amortized over the remaining three-year term of the software subscription agreement, rather than expensed as incurred. The costs were expensed from July 1, 2024 to March 1, 2026, when the ERP system went live. Any adjustment would be non-cash and would not affect revenue or cash balances.
InfuSystem Holdings, Inc. (INFU) announced it will report third-quarter 2026 financial results before the market opens on November 3, 2026, and hold an investor conference call that day at 9:00 a.m. Eastern Time. Participants can join by telephone or through a live webcast on the company’s website. A replay will be available online or by telephone through February 3, 2027.
InfuSystem Holdings, Inc. reported that EVP-Chief HR Officer Jerod Funke’s 7,157 restricted stock units fully vested on October 9, 2026 and converted one-for-one into 7,157 common shares. On that date, 2,101 common shares were withheld for the tax liability associated with vesting and settlement, at a reported price of $13.56 per share.
InfuSystem Holdings, Inc. (INFU) announced that it will host an investor webcast presentation on September 24, 2026 at 2:00 p.m. Eastern Time. The event will feature an introductory presentation by President and CEO Carrie Lachance and EVP/CFO Barry Steele covering the company’s corporate strategy, business model and growth initiatives.
Following the formal presentation, investors will be able to submit questions through an interactive Q&A portal. Access to the webcast will be provided via a Zoom registration link and through the company’s investor relations website. The related press release is furnished as an exhibit to this report under a Regulation FD disclosure.
InfuSystem Holdings, Inc (INFU) reported a Form 4 for director Scott Shuda reflecting an indirect disposition of 20,000 shares of Common Stock on September 10, 2026, classified as an "other" non-cash transaction. The shares were distributed by Meridian OHC Partners, LP to one limited partner, and are held through entities over which Mr. Shuda has voting and dispositive power but for which he disclaims beneficial ownership for Rule 13d-3 purposes. After this transaction, 278,383 shares are reported as indirectly held and 94,000 shares as directly held. No trades are reported under a Rule 10b5-1 plan.
InfuSystem Holdings reported Q2 2026 net revenues of $36,933 (in thousands), up 2.6% from $36,002 (in thousands), as gross margin increased to 58.0%. Net income for the quarter rose to $3,231 (in thousands), or $0.15 diluted EPS, compared with $2,599 (in thousands), or $0.12. For the first half of 2026, net revenues were $70,617 (in thousands) and net income was $4,248 (in thousands), versus $70,718 and $2,332 (in thousands) a year earlier.
Patient Services revenue grew 15.2% in Q2, driven by higher Oncology volume and 154% growth in Wound Care, including new compression therapy products, while Device Solutions revenue declined 16.1% following a restructured GE Healthcare services contract and a prior-period rental buyout. Total assets were $97,700 (in thousands) with long‑term debt of $20,424 (in thousands) and available liquidity of $55,207 (in thousands). Operating cash flow was $7,747 (in thousands) for the first half, supporting continued investment in medical equipment and IT, and the board authorized a new $20,000 (in thousands) share repurchase program through June 30, 2028.
InfuSystem Holdings, Inc. outlines a home healthcare services platform that shifts complex therapies from hospitals to the home through two revenue engines: Patient Services and Device Solutions. Patient Services generates about 60% of revenue and Device Solutions about 40%, supported by 800+ payer contracts and relationships with 18 of the top 20 U.S. hospital systems.
For 2025, net revenue was $143.4 million, up 6% year over year, with adjusted EBITDA of $31.5 million, up 25%, driving a 21.9% adjusted EBITDA margin and 8.3% operating margin. Wound Care treatment revenue grew 103% in 2025 as a key adjacent therapy, while LTM adjusted EBITDA margin reached 22.4% as of the second quarter of 2026. As of June 30, 2026, equity was $59.1 million, total long-term debt $20.4 million, net leverage 0.61x and total available liquidity $55.2 million, backed by $23.4 million of cash provided by operations. Management targets 6–8% pro forma revenue growth and adjusted EBITDA margins in the low-to-mid 20% range over time.
InfuSystem Holdings, Inc. reported second quarter 2026 net revenues of $36.9 million, up 2.6% from $36.0 million a year earlier, with record revenue driven by strong Patient Services growth. Patient Services revenue rose to $24.8 million, up 15.2%, while Device Solutions revenue declined to $12.1 million, down 16.1%, reflecting a previously restructured GE Healthcare biomedical services contract and lower equipment sales.
Gross profit increased to $21.4 million with gross margin improving to 58.0%, supported by higher Device Solutions margins. Net income was $3.2 million, or $0.15 per diluted share, versus $2.6 million, or $0.12, in 2025. Non-GAAP Adjusted EBITDA rose to $8.6 million, a 7.6% increase, with margin of 23.4%. Liquidity totaled $55.2 million as of June 30, 2026, and net debt was $19.5 million. The company repurchased $3.5 million of stock in the quarter and reaffirmed full-year 2026 guidance for pro-forma net revenue growth of 6%–8% and Adjusted EBITDA margins in the mid to low 20% range.
BlackRock, Inc. reports beneficial ownership of common stock of InfuSystem Holdings, Inc. as of June 30, 2026. BlackRock reports beneficial ownership of 1,286,129 shares of common stock, representing 6.4% of the class.
BlackRock has sole voting power over 1,269,273 shares and sole dispositive power over 1,286,129 shares, with no shared voting or dispositive power. The filing aggregates holdings of certain BlackRock business units. Various underlying clients have rights to dividends and sale proceeds, but no single client reportedly holds more than five percent of InfuSystem’s outstanding common shares.